Cas:51234-21-0 Salbutamol Related Compound 2 manufacturer & supplier

Chemical Name:Salbutamol Related Compound 2

CAS.NO:51234-21-0

Synonyms:Salbutamol Related Compound 2

Molecular Formula:N/A

Molecular Weight:N/A

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Salbutamol Related Compound 2 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Salbutamol Related Compound 2 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Salbutamol Related Compound 2 Use and application,Salbutamol Related Compound 2 technical grade,usp/ep/jp grade.

Related News: The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. Salbutamol Related Compound 2 manufacturer International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation. Salbutamol Related Compound 2 supplier The continuous acceleration of the industrial transfer process has provided a huge market space for the fine chemical intermediate industry. Salbutamol Related Compound 2 vendor The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. Salbutamol Related Compound 2 factory Onconova has conducted trials with two other research compounds and has a pre-clinical program with a CDK4/6 and Ark5 inhibitor, ON 123300.